The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer. After changing its strategy and organization in 2018, Aqilion decided to transfer its holdings in Belina AB to its founder and innovator since Aqilion is no longer an ideal partner for the continued development of Belina as a company and commercialization of its future product.
Many years of research at Lund University, in Sweden, have shown that long-term treatment with a specific pharmaceutical substance combined with current treatment regimens for breast cancer can lead to significantly improved survival. The innovation is based on research in oncology under the leadership of Professor Håkan Olsson at Lund University. After investigating data and registry studies, the research group found higher survival among patients treated with an approved medication in parallel with their breast cancer treatment. Belina was founded as an extremely early innovation project within what was known as the PULS group at the time, currently known as Aqilion.
“The innovation is based on large registry studies and solid research in breast cancer and is extremely interesting. Based on Aqilion’s new strategy, we have determined that we are no longer the right partner for commercial development of the project and the Board of Directors has therefore decided to transfer Aqilion’s stake in Belina to its founder. We hope that by doing so, Håkan Olsson’s research group will be able to continue to take advantage of new data and pave the way so their discovery will benefit patients in the future,” says Sarah Fredriksson, CEO of Aqilion.
Date: April 29, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Sweden BIO
